For your nebuliser therapy, the amount of medication that reaches the lungs is the key factor. This requires nebulisers that can produce sufficiently fine aerosol droplets in as short a time as possible.
PARI nebulisers are often recommended in the package inserts of medications for inhalation. Thanks to their world-wide availability and high quality, our PARI nebulisers are often used in clinical studies of medications. One factor for the effectiveness of the nebuliser is particularly important: the RDDR, which stands for Respirable Drug Delivery Rate. This describes the amount of respirable medication generated by the nebuliser and inhalation device per minute, and therefore the amount of the medication available to the person using the product. It is important to note that only aerosols that are smaller than 5 µm are defined as respirable in medical terms and can therefore reach the lungs. Larger droplets may, for example, remain stuck in the throat before they reach the lungs.
Of course, there are other factors that also determine how much aerosol actually reaches the lungs. For example, how patient the adult or child is to carry on the inhalation to the end and whether a mouthpiece or mask is used.
PARI nebulisers have come out top in various comparative studies with commercially available nebulisers for children and adults.1,2
Summary: Nebulisers with a high RDDR are beneficial for you as a patient. They save precious time with patient-friendly short nebulisation times while delivering high doses of the desired medication.
1 Walz-Jung H et al., Pneumologie 2018
2 Walz-Jung H et al., Poster GPP 2013